Presentation is loading. Please wait.

Presentation is loading. Please wait.

DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large.

Published byPreston Merritt Modified over 8 years ago

Similar presentations

Presentation on theme: "DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large."— Presentation transcript:

1 DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large blood bank settings Lutz Pichl, DRK-Blutspendedienst West Christine Jork, DRK-Blutspendedienst NSTOB Lutz Pichl, DRK-Blutspendedienst West

2 DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern DRK-BSD West DRK-BSD NSTOB Springe Hagen

3 DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern BSD NSTOBBSD West Donations/year (2005) Samples/Day 1.15 mio ~ 4.000 1.26 mio ~ 4.000 Viral parameters HCV, HIV-1, HBV, HAV, PVB19 Routine testing with CAP/CTM96 since 1st Nov. 2005 1st July 2005 CAP/CTM96 Systems 6 x9 x

4 DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern BSD NSTOBBSD West CAP/CTM96 combined via docking station for HBV, HCV and HIV-1 + ventilation shaft for waste air 2 CAP/CTM96 for HCV 2 CAP/CTM96 for HIV-1 1 CAP/CTM96 for HBV 1 CAP for TNAI  HAV/PVB19 RealArt LC PCR Reagents (QIAGEN Diagnostics), LightCycler 1.2 (Roche) 3 CAP/CTM96 for HCV 3 CAP/CTM96 for HIV-1 3 CAP/CTM96 for HBV 2 CAP for TNAI  HAV/PVB19 RealArt LC PCR Reagents (QIAGEN Diagnostics), LightCycler 2.0 (Roche) System configuration

5 DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern BSD NSTOBBSD West Samples tested 668,469 (11/2005 – 05/2006) Pool size  96 Invalidity rate (HCV / HIV-1 / HBV) Failure rate 0.9 % (hardware error) < 0.2 % (clot, hardware error) NAT only positives 842,751 (07/2005 -05/2006) HCV: 2 (05) 2 (06) HBV: 1 HCV: Ø 0.27 % HIV-1: Ø 0.12 % HBV: Ø 0.05 % HIV-1: 2 (06) HBV: 1 (06) HCV: Ø 1.68 % HIV-1: Ø 0.15 % HBV: Ø 0.14 %

6 DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern 95% detection limits BSD NSTOBBSD West HBV 675 IU WHO /ml SD251 IU WHO /ml SD HCV 582 IU WHO /ml SD624 IU WHO /ml SD HIV-1 4315 IU WHO /ml SD7876 IU WHO /ml SD PVB19 5784 IU WHO /ml SD5735 IU WHO /ml SD HAV 21420 IU WHO /ml SD6157 IU WHO /ml SD SD = single donation in pool of 96 samples

7 DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Turn around time CAP/CTM Maintenance Sample Preparation 1 h NA Extraction 2 h Amplification & Detection HIV-1 3h 15‘ HCV 2h 40‘ HBV 2h 10‘ HAV/PVB 50‘ Pooling 0,5 h Result Validation Data Transfer (LIMS) 15-30‘ 6 a.m. ~1 p.m.

8 DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern ProCon fully automated intensive maintenance caused by high system complexity short hands-on time additional manual result interpretation IVD conform only for single samples off label use for minipool testing; extensive validation studies virus enrichment steps unnecessary high sample volume (1050 µl brutto volume) automation of front end sample handling is users responsibility  in-house solutions Pros & Cons of CAP/CTM96 System

Download ppt "DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large."

Similar presentations

Marta José, Instituto Grifols S.A., Barcelona, SPAIN

Marta José, Instituto Grifols S.A., Barcelona, SPAIN
Dr. Thaweesak Tirawatnapong Chula Medical Research Center (Chula MRC)

Dr. Thaweesak Tirawatnapong Chula Medical Research Center (Chula MRC)
National Institute for Biological Standards and Control Assuring the quality of biological medicines Proposal for a Hepatitis A genotype panel Rob Anderson.

National Institute for Biological Standards and Control Assuring the quality of biological medicines Proposal for a Hepatitis A genotype panel Rob Anderson.
Simplification, cost-reduction strategies and examples from the field Teri Roberts Diagnostics Advisor Médecins Sans Frontières, Access Campaign 7th.

Simplification, cost-reduction strategies and examples from the field Teri Roberts Diagnostics Advisor Médecins Sans Frontières, Access Campaign 7th.
PCS Conference Reducing Inhibition of RT-PCR in plasma samples from cadavers Dr Simon Carne National Transfusion Microbiology Reference Laboratory (NTMRL)

PCS Conference Reducing Inhibition of RT-PCR in plasma samples from cadavers Dr Simon Carne National Transfusion Microbiology Reference Laboratory (NTMRL)
Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Paris, May 2004SoGAT XVII SoGAT and the Development of Standards Harvey Holmes Division of Retrovirology NIBSC, UK.

Paris, May 2004SoGAT XVII SoGAT and the Development of Standards Harvey Holmes Division of Retrovirology NIBSC, UK.
Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:

Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:
Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, 28-29 May, 2009, Brussels, Belgium.

Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.
COBAS TaqMan 48 Sales Brochure

COBAS TaqMan 48 Sales Brochure
Full characterization of HAV RNA window period positive blood donations in Germany SoGAT XVIII Bethesda.

Full characterization of HAV RNA window period positive blood donations in Germany SoGAT XVIII Bethesda.
R Diagnostics June 19, 2003 WNV FDA BPAC MeetingPCR NAT Blood Screening TaqScreen West Nile Virus Program - Roche Update James L. Gallarda, Ph.D. Roche.

R Diagnostics June 19, 2003 WNV FDA BPAC MeetingPCR NAT Blood Screening TaqScreen West Nile Virus Program - Roche Update James L. Gallarda, Ph.D. Roche.
 The HIV virus can mutate in HIV positive patients taking Anti-Retroviral Therapy (ART)  Their HIV strain has now become drug resistant (DR), and their.

 The HIV virus can mutate in HIV positive patients taking Anti-Retroviral Therapy (ART)  Their HIV strain has now become drug resistant (DR), and their.
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.

PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
COBAS AmpliPrep/Cobas TaqMan HIV-1 Test

COBAS AmpliPrep/Cobas TaqMan HIV-1 Test
Generic Automated Sample Preparation for Commercial NAT Assays

Generic Automated Sample Preparation for Commercial NAT Assays
Real-time PCR automated solution for food pathogen testing

Real-time PCR automated solution for food pathogen testing
Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.

Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.
BioLife Plasma Services Experience with HBV NAT Testing

BioLife Plasma Services Experience with HBV NAT Testing
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.

HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.

Similar presentations

Ads by Google